Jump to content

Beximco Pharma

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 01:57, 16 June 2023 (Alter: title. Add: date. | Use this bot. Report bugs. | Suggested by Eastmain | Category:Manufacturing companies based in Dhaka | #UCB_Category 17/35). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Beximco Pharmaceuticals Ltd
Company typeLimited
DSE: BXPHARMA
LSE: BXP
IndustryPharmaceutical
Founded1980
HeadquartersDhanmondi, Dhaka, Bangladesh
Key people
Nazmul Hassan Papon (Managing Director)
RevenueIncreaseUS$300 million (2020)
Increase ৳5.1 billion (2018)[1]
IncreaseUS$42 million (2020)
Number of employees
4,523[1]
Websitewww.beximcopharma.com

Beximco Pharmaceuticals Ltd also known as Beximco Pharma, is a pharmaceutical company in Bangladesh.[2] It is a part of Bangladesh Export Import Company Limited (BEXIMCO).[3]

Corporate history

Beximco Pharma was founded in 1976 and started operations in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of United States.[4] Today Beximco Pharma manufactures and markets its own branded generics for several diseases including AIDS, cancer, asthma, hypertension, and diabetes for both national and international markets. It was the first drug company from Bangladesh to sell its products in the US.[5]

In May 2020, the company introduced the world's first generic remdesivir for COVID-19 treatment.[6][7][8] Beximco Pharma became the first company to obtain production and marketing authorization for molnupiravir, the first and only specific oral anti-covid drug in Bangladesh along with Eskayef Pharmaceuticals. Beximco Pharma's branded generic version of molnupiravir is being marketed as Emorivir.

Factories

Beximco Pharma manufacturing facilities are spread across a 20-acre (81,000 m2) site located in Dhaka, Bangladesh. The facilities consist of a number of purpose-built plants, including a new Oral Solid Dosage (OSD) plant. The site includes manufacturing facilities as well as a research laboratory and a number of warehouses. The plant and machinery of the facilities were designed, produced and installed by partners from Germany, Switzerland, Sweden, Italy and the United Kingdom, amongst others.

Exports

On August, 2007, Beximco exported its medicines to the Philippines, the 5th country of the 10-member Association of South East Asian Nations (ASEAN) to import Beximco's drugs. Beximco Managing Director Nazmul Hassan said that exports to the Philippines include metered dose inhalers, and nasal sprays, and other medications. The Philippine pharmaceutical market ($1.3 billion in 2007), is highly dependent on imported medicines.[9]

References

  1. ^ a b "Beximco Pharma Annual Report 2018-19" (PDF). Retrieved 23 December 2019.
  2. ^ "BD firm plans to export version of Tamiflu". Daily Times. 2006-04-05. Archived from the original on 2011-06-06. Retrieved 2008-03-08.
  3. ^ "Bangladesh forays into US market with Beximco Pharma". bdnews24.com. Retrieved 2016-10-03.
  4. ^ Letter, The Pharma. "Beximco Pharma Q3 revenue up". www.thepharmaletter.com. Retrieved 2016-10-03.
  5. ^ "US FDA approves Beximco Pharma's blood pressure drug". Dhaka Tribune. Archived from the original on 2016-09-30. Retrieved 2016-10-03.
  6. ^ "Beximco introduces remdesivir for Covid-19 treatment". The Daily Star. 2020-05-21. Retrieved 2020-05-24.
  7. ^ "Beximco Pharma introduces world's first generic Remdesivir for COVID-19 treatment". The Financial Express. Dhaka. Retrieved 2020-05-24.
  8. ^ Siddiqui, Zeba (2020-05-05). "Exclusive: Bangladesh's Beximco to begin producing COVID-19 drug remdesivir - COO". Reuters. Retrieved 2021-03-06.
  9. ^ "Bangladesh Beximco exports drugs to Philippines". Reuters. 29 August 2007.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Beximco_Pharma&oldid=1160367314"